| Development of the neuroimmune modulator ibudilast for the treatment of alcoholism: a randomized, placebo-controlled, human laboratory trial LA Ray, S Bujarski, S Shoptaw, DJO Roche, K Heinzerling, K Miotto Neuropsychopharmacology 42 (9), 1776-1788, 2017 | 111 | 2017 |
| State-of-the-art behavioral and pharmacological treatments for alcohol use disorder LA Ray, S Bujarski, E Grodin, E Hartwell, RJ Green, A Venegas, AC Lim, ... The American journal of drug and alcohol abuse 45 (2), 124-140, 2019 | 109 | 2019 |
| Alcohol, tobacco, and marijuana consumption is associated with increased odds of same-day substance co-and tri-use DJO Roche, S Bujarski, R Green, EE Hartwell, AM Leventhal, LA Ray Drug and alcohol dependence 200, 40-49, 2019 | 99 | 2019 |
| Subjective Response to Alcohol Among Alcohol‐Dependent Individuals: Effects of the Mu‐Opioid Receptor (OPRM1) Gene and Alcoholism Severity LA Ray, S Bujarski, J MacKillop, KE Courtney, PM Monti, K Miotto Alcoholism: Clinical and Experimental Research, 2012 | 90 | 2012 |
| The Effects of Drinking Goal on Treatment Outcome for Alcoholism. S Bujarski, SS O'Malley, K Lunny, LA Ray American Psychological Association, 2012 | 84 | 2012 |
| Pharmacogenetics of Naltrexone in Asian Americans: A Randomized Placebo-Controlled Laboratory Study LA Ray, S Bujarski, PF Chin, K Miotto Neuropsychopharmacology 37 (2), 445-455, 2011 | 81 | 2011 |
| Understanding naltrexone mechanism of action and pharmacogenetics in Asian Americans via behavioral economics: a preliminary study. S Bujarski, J MacKillop, LA Ray Experimental and clinical psychopharmacology 20 (3), 181, 2012 | 77 | 2012 |
| Differences between treatment-seeking and non-treatment-seeking participants in medication studies for alcoholism: do they matter? LA Ray, S Bujarski, MM Yardley, DJO Roche, EE Hartwell The American journal of drug and alcohol abuse 43 (6), 703-710, 2017 | 75 | 2017 |
| Subjective response to alcohol as a research domain criterion LA Ray, S Bujarski, DJO Roche Alcoholism: Clinical and Experimental Research 40 (1), 6-17, 2016 | 70 | 2016 |
| The effects of naltrexone on subjective response to methamphetamine in a clinical sample: a double-blind, placebo-controlled laboratory study LA Ray, S Bujarski, KE Courtney, NR Moallem, K Lunny, D Roche, ... Neuropsychopharmacology 40 (10), 2347-2356, 2015 | 68 | 2015 |
| Subjective response to alcohol and associated craving in heavy drinkers vs. alcohol dependents: an examination of Koob's allostatic model in humans S Bujarski, LA Ray Drug and alcohol dependence 140, 161-167, 2014 | 61 | 2014 |
| Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol JR Ashenhurst, S Bujarski, LA Ray Pharmacology Biochemistry and Behavior 103 (2), 253-259, 2012 | 61 | 2012 |
| The association of alcohol severity and sleep quality in problem drinkers EE Hartwell, S Bujarski, S Glasner-Edwards, LA Ray Alcohol and alcoholism 50 (5), 536-541, 2015 | 60 | 2015 |
| Ibudilast, a neuroimmune modulator, reduces heavy drinking and alcohol cue-elicited neural activation: a randomized trial EN Grodin, S Bujarski, B Towns, E Burnette, S Nieto, A Lim, J Lin, K Miotto, ... Translational psychiatry 11 (1), 355, 2021 | 55 | 2021 |
| Naltrexone effects on subjective responses to alcohol in the human laboratory: A systematic review and meta‐analysis LA Ray, RJ Green, DJO Roche, M Magill, S Bujarski Addiction biology 24 (6), 1138-1152, 2019 | 47 | 2019 |
| Differences in the subjective and motivational properties of alcohol across alcohol use severity: application of a novel translational human laboratory paradigm S Bujarski, JD Jentsch, DJO Roche, VA Ramchandani, K Miotto, LA Ray Neuropsychopharmacology 43 (9), 1891-1899, 2018 | 46 | 2018 |
| Interactive effects of OPRM1 and DAT1 genetic variation on subjective responses to alcohol LA Ray, S Bujarski, LM Squeglia, JR Ashenhurst, RF Anton Alcohol and Alcoholism 49 (3), 261-270, 2014 | 44 | 2014 |
| The CRHR1 gene, trauma exposure, and alcoholism risk: a test of G× E effects LA Ray, M Sehl, S Bujarski, K Hutchison, S Blaine, MA Enoch Genes, Brain and Behavior 12 (4), 361-369, 2013 | 44 | 2013 |
| Overcoming the “Valley of Death” in medications development for alcohol use disorder LA Ray, S Bujarski, DJO Roche, M Magill Alcoholism: Clinical and Experimental Research 42 (9), 1612-1622, 2018 | 43 | 2018 |
| The relationship between methamphetamine and alcohol use in a community sample of methamphetamine users S Bujarski, DJO Roche, K Lunny, NR Moallem, KE Courtney, V Allen, ... Drug and alcohol dependence 142, 127-132, 2014 | 43 | 2014 |
